Fierce Pharma August 29, 2023
As he talks about the future of cell therapy, the enthusiasm of Cellares CEO Fabian Gerlinghaus is unmistakable.
“There’s about 2,800 cell therapies in development worldwide,” Gerlinghaus said in an interview. “The FDA projects that they’ll be approving 10 to 20 new cell and gene therapies every single year starting in 2025. There’s all of these—there’s thousands of drugs coming down the pipe.”
It’s an exciting time for a cell and gene therapy manufacturer—especially one that believes it has developed a game-changing production platform.
Ready to bet on Cellares’ platform is cell therapy leader Bristol Myers Squibb. Monday, the companies unveiled a partnership in which BMS will use Cellares’ robotic Cell Shuttle platform for automated manufacturing of a CAR-T cell...
Today's Sponsors
Today's Sponsor